2016
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infection
2013
Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance
Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance. Antimicrobial Agents And Chemotherapy 2013, 57: 6154-6157. PMID: 24080665, PMCID: PMC3837895, DOI: 10.1128/aac.01229-13.Peer-Reviewed Original ResearchConceptsEVG/COBIBaseline valuesEffect of elvitegravirOpioid-dependence therapiesHIV-seronegative subjectsConcentration-time curveChronic methadone maintenanceDependence therapyOpioid withdrawalMethadone pharmacokineticsDosing periodMethadone maintenanceHistorical controlsPharmacodynamic studiesPharmacokinetic parametersMethadoneCobicistatElvitegravirMean areaAUCtauPharmacodynamicsCmaxSubjectsCOBISteady-state evaluationA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysiciansPharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedicationsDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine
McCance‐Katz E, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal On Addictions 2006, 15: 23-34. PMID: 16449090, DOI: 10.1080/10550490500419029.Peer-Reviewed Original ResearchConceptsDrug interactionsObjective Opioid Withdrawal ScaleSeven-day study periodNon-nucleoside reverse transcriptase inhibitorMini-Mental State ExaminationOpioid withdrawal symptomsOpioid Withdrawal ScaleClinical pharmacology studiesOpioid-dependent individualsReverse transcriptase inhibitorLAAM treatmentMethadone clearanceOpioid pharmacokineticsOpioid therapyOpioid toxicityAntiretroviral medicationsHIV outcomesPharmacodynamic interactionsCardiac toxicityWithdrawal symptomsAdverse symptomsTranscriptase inhibitorWithdrawal ScaleAcetyl methadolPharmacology studies
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
2004
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
2003
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusNondetectable viral loadCD4 lymphocyte countDrug treatmentDrug usersLymphocyte countViral loadHIV therapyBaseline HIV-1 RNA levelsNeedle exchangeHealth servicesHIV-1 RNA levelsPilot studyPotent antiretroviral combinationUtilization of HAARTActive antiretroviral therapyAntiretroviral therapy regimensHIV-1 RNACommunity-based health interventionsAdverse side effectsActive drug usersFormal drug treatmentImmunodeficiency syndrome (AIDS) incidenceSmall pilot studyActive heroin injectorsThe Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment
2002
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Rainey PM, Friedland GH, Snidow JW, McCance‐Katz E, Mitchell SM, Andrews L, Lane B, Jatlow P. The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects. American Journal On Addictions 2002, 11: 66-74. PMID: 11876585, DOI: 10.1080/10550490252801657.Peer-Reviewed Original ResearchConceptsSerum concentrationsCombination tabletSerum concentration-time curveMethadone dose changesMethadone serum concentrationsMaximum serum concentrationOpiate-dependent subjectsConcentration-time curveVolume of distributionCombination pharmacotherapyMethadone pharmacokineticsTerminal eliminationCo-administrationDose changesMean areaSignificant differencesPharmacokineticsSubjectsSubject studyHIVPharmacotherapyPatientsAdministration
2000
Interaction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCanceKatz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. PMID: 10969348, DOI: 10.1097/00126334-200007010-00007.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrationsInteraction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCance-Katz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. DOI: 10.1097/00042560-200007010-00008.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrationsInteractions between methadone and medications used to treat HIV infection: a review.
Gourevitch M, Friedland G. Interactions between methadone and medications used to treat HIV infection: a review. Annals Of Global Health 2000, 67: 429-36. PMID: 11064494.Peer-Reviewed Original ResearchConceptsMetabolic enzyme inductionAntiretroviral regimensAntiretroviral therapyHIV infectionPharmacokinetic interactionsNarcotic withdrawalPharmacologic interactionsMedication interactionsSpecific HIVPharmacologic studiesOpiate dependenceSide effectsMedicationsElectronic databasesMethadoneClinical implicationsHIVAdditional publicationsEnzyme inductionFurther studiesHuman subjectsScientific meetingsCurrent understandingRegimensPharmacotherapy
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatientsMethadone and antiretroviral medications, part II.
Gourevitch M, Friedland G. Methadone and antiretroviral medications, part II. Infectious Diseases 1999, 11: 37, 43, 45-6. PMID: 11367102.Peer-Reviewed Original ResearchMethadone and antiretroviral medications, part I.
Gourevitch M, Friedland G. Methadone and antiretroviral medications, part I. Infectious Diseases 1999, 11: 30-1 contd. PMID: 11366210.Peer-Reviewed Original Research
1998
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262)
McCanceKatz E, Rainey P, Jatlow P, Friedland G. Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 435-443. PMID: 9715839, DOI: 10.1097/00042560-199808150-00004.Peer-Reviewed Original ResearchConceptsInjection drug usersMethadone treatmentChronic methadone treatmentMethadone-maintained patientsHeroin-addicted patientsMethadone effectsZDV doseZDV exposureZDV pharmacokineticsZDV treatmentZidovudine dispositionZidovudine therapyHIV diseaseMethadone levelsPharmacokinetic interactionsTherapeutic rangeRenal clearanceToxicity surveillanceSide effectsDrug usersDrug efficacyZDVClearanceAUCPatients
1996
A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY.
Gourevitch M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, Friedland G, Klein R. A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. American Journal Of Public Health 1996, 86: 1112-5. PMID: 8712270, PMCID: PMC1380622, DOI: 10.2105/ajph.86.8_pt_1.1112.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seronegative patientsHIV-seropositive patientsDrug usersHIV infectionEarly syphilisProspective studyHuman immunodeficiency virus (HIV) infectionHigh-risk sexual activityPercent of HIVImmunodeficiency virus infectionMethadone maintenance treatmentDrug-using womenMultiple sex partnersDiagnosis of syphilisEarly syphilis incidenceFemale drug usersHIV seroconversionHIV seroconvertersMaintenance treatmentIncidence rateIndependent riskVirus infectionSyphilis incidencePatients
1995
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.
Hartel D, Schoenbaum E, Selwyn P, Kline J, Davenny K, Klein R, Friedland G. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal Of Public Health 1995, 85: 83-88. PMID: 7832267, PMCID: PMC1615273, DOI: 10.2105/ajph.85.1.83.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentHeroin useMaintenance treatmentHigh-dose methadone maintenanceCocaine useMethadone dosage levelsNonusers of cocaineMethadone doseLogistic regression statistical modelMethadone dosageMethadone patientsTreatment complianceMethadone maintenanceIndependent associationTreatment durationCross-sectional samplePatientsAlcohol useDosage levelsCocaine usersSocioeconomic factorsTreatmentFurther investigationCocaineNonusers